{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-25-000021","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2025-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.726017+00:00","generated_at":"2026-05-24T17:38:16.789077+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ANI Pharmaceuticals receives FDA approval to expand ILUVIEN label for chronic non-infectious uveitis","bullets":["FDA approved ILUVIEN for chronic non-infectious uveitis affecting posterior segment (NIU-PS), expanding beyond DME.","ANI plans to market ILUVIEN under the combined label in the U.S. later this year.","Extended supply agreement with Siegfried through 2029; equipment upgrade and capacity expansion planned.","ILUVIEN is already approved for both DME and NIU-PS in 17 European countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-25-000021","json":"https://secwatch.observer/filing/0001023024-25-000021.json","markdown":"https://secwatch.observer/filing/0001023024-25-000021.md","text":"https://secwatch.observer/filing/0001023024-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000021/0001023024-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000021/ani-20250314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T17:38:16.789077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}